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Abstract
Chronic hepatitis C virus (HCV) infection is a growing global health problem. HCV is a 
leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) and is 
associated with more than 30 extrahepatic manifestations (EHMs). Although cryoglobu-
linemia is the main pathological cause of neurologic EHMs, HCV viral replication in 
the brain itself must also be taken into consideration. The most significant neurological 
manifestations of HCV chronic infection are stroke, leukoencephalopathy, encephalo-
myelitis/myelitis, and peripheral neuropathy. The most significant neuropsychological 
manifestations of HCV infection are fatigue, depression, anxiety, and cognitive dysfunc-
tion. Antiviral HCV treatment should be the first-line treatment for managing mild-to-
moderate vascular and neurologic symptoms; most of EHMs improve or even resolve if 
antiviral treatment starts on time.
Keywords: hepatitis C virus, extrahepatic manifestations, cryoglobulinemia, neurological 
manifestations, neuropsychological manifestations, antiviral treatment
1. Introduction
Chronic hepatitis C virus (HCV) infection is a growing global health problem affecting an 
estimated 185 million people (a prevalence rate of 2.8%) [1]. HCV is a leading cause of chronic 
hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) and is associated with more than 30 
extrahepatic manifestations (EHMs) [2].
EHMs are immunologic and rheumatologic in their pathophysiology: they are caused by 
B-cell proliferation, which produce monoclonal and polyclonal autoantibodies and then acti-
vate rheumatoid factor or have cryoglobulin properties.
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Cryoglobulinemia is the most frequent and best-studied EHM of HCV infection. It is detected 
in up to 50% of HCV-infected patients. Cryoglobulins (CGs) are cold-precipitable immu-
noglobulins, which make vascular deposits and then cause inflammation and occlusion of 
small- and medium-size blood vessels. Typical clinical manifestations of cryoglobulinemia 
are cutaneous purpura, arthralgias, and membranous proliferative glomerulonephritis. Also, 
up to 17–60% of patients with cryoglobulinemia develop peripheral neuropathy. Central ner-
vous system (CNS) involvement occurs in approximately 6% of cases. CGs are also a risk fac-
tor for carotid plaque formation, hepatic fibrosis, and liver steatosis [3].
Although cryoglobulinemia is the main pathological cause of neurologic EHMs, special con-
sideration must be given to HCV viral replication in brain itself. It is believed that there are 
specific brain HCV variants that cause neurotoxicity (induce apoptosis). So far, it has been 
hypothesized that microglial cells (CNS macrophages) are the main targets for HCV entry 
into the CNS. Detection of replicative intermediate forms of HCV RNA and viral proteins 
within the CNS has led to this conclusion. Furthermore, sequence analysis of HCV residing in 
liver and brain has suggested an evolutionary path of a virus to infect the CNS [4].
2. Neurological manifestations
HCV-related CNS complications encompass a wide spectrum of disorders ranging from cere-
brovascular events to autoimmune syndromes.
1. Acute cerebrovascular events can sometimes be the initial manifestation of HCV infection.
2. Acute or subacute encephalopathic syndromes have been associated with diffuse involve-
ment of the white matter in HCV chronically infected patients with CG and/or circulating 
anticardiolipin antibodies.
3. The occurrence of an immune-mediated process induced by HCV causes inflammatory 
disorders such as acute encephalitis, encephalomyelitis, and meningoradiculitis/poly-
radiculitis; there are reports of patients with rapidly evolving acute leukoencephalitis or 
fatal progressive acute encephalomyelitic syndromes [3].
4. HCV has been connected with the metabolic syndrome so HCV infection represents an 
independent risk factor for increased carotid wall thickness and plaque formation, thus 
contributing to significant cerebrovascular mortality [3].
Neurological manifestations are most often caused by occlusive vasculopathy (due to mixed 
cryoglobulinemia), ANCA-associated CNS vasculitis or anti-phospholipid associated syn-
drome. In addition, HCV infection may increase the risk of atherosclerosis and earlier stroke 
through predisposition to metabolic diseases such as type 2 diabetes [5].
3. Neuropsychological manifestations
Fatigue, cognitive dysfunction, and mood alterations display a profound effect on social and 
physical function of HCV-infected subjects, thus impacting health-related quality of life (HRQL).
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Chronic fatigue (often called “brain fog”) is perceived as a sensation of physical and mental 
exhaustion, and when severe, it is accompanied by deficits of attention tasks, anomia, and 
word-finding difficulties, in the absence of verbal memory or cognitive ability impairments [6].
It has been found that 28% of chronically HCV-infected subjects have depression [7]. 
The occurrence of depression has been attributed to psychological factors, or to specific 
determinants, including immune mechanisms, derangement of the blood–brain-barrier 
integrity, viral replication within the CNS, iatrogenic factors, or altered dopaminergic 
and serotoninergic transmission [7]. It is very important to diagnose such manifestations 
because in moderate-to-severe depression it is mandatory to reduce or discontinue inter-
feron treatment.
Investigation of a large population of patients with chronic HCV infection has disclosed the 
occurrence of subclinical cognitive dysfunction (alterations in verbal and learning skills, con-
centration, attention, working memory) in 18% of subjects [8].
4. Peripheral neuropathies
In patients with HCV, the involvement of the peripheral nervous system (PNS) ranges 
from 26 to 86% in accordance with the disease stage [9]. Peripheral neuropathies occur 
mostly in the presence of circulating CG which causes ischemic nerve changes, as a conse-
quence of small vessel vasculitis, or, less frequently, necrotizing arteritis of medium-sized 
vessels [9].
In patients without CG, immune complexes or HCV-induced autoimmune mechanisms may play 
a pathogenetic role in inducing vascular and perivascular inflammation, which may be driven by 
an intrinsic nerve population of immunocompetent and potentially phagocytic cells [10].
Many patients develop a symmetrical sensory or sensorimotor axonal-type polyneuropathy, 
with sensory loss and weakness in distal regions of limbs [11]. Others present with mono-
neuropathies and mononeuropathy multiplex or the asymmetrical sensory variants such as 
large-fiber sensory neuropathy (LFSN) and small-fiber sensory polyneuropathy (SFSN) [12]. 
Cranial nerves are usually spared.
One must also take into consideration that HCV-infected patients can have multiple neuro-
logical/neuropsychological manifestations.
5. Impact of HCV treatment on neurological/neuropsychiatric disorders
Antiviral HCV treatment is the first-line treatment for managing mild-to-moderate neuro-
logic/neuropsychologic symptoms. However, patients on interferon (IFN) therapy should be 
monitored as IFN therapy may aggravate the symptoms of peripheral neuropathies (IFN can 
create the pathogenic inflammatory environment for neuropathy) [4].
Tricyclic antidepressants, local anesthetics, and opioids may be required to the standard anti-
viral therapy for treatment of acute pain attacks [4].
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Rituximab is also useful in treating neuropathic pain, as it acts by inhibiting cryoglobulin 
production and its pathogenic cascade [4].
If EHMs do not improve after antiviral treatment, the use of immunosuppressants is also a 
treatment possibility, but only as a last resort in patients not responding to antiviral treatment 
or with refractory disease (because of possible worsening of viral infection) [4].
Also, when discussing neuropathological and neuropsychiatric manifestations in HCV-
infected patients, it is very important to distinguish between neuropsychiatric diseases caused 
by the virus itself and those caused by the treatment.
There are many neurological side effects of HCV treatment: up to 70% of HCV patients 
treated with IFN may develop depression [13]. Neurovegetative symptoms like loss of appe-
tite, fatigue, sexual impairment, and psychosomatic symptoms start to occur within 4 weeks 
of IFN treatment [13]. The confusional state induced by IFN is associated with psychomotor 
retardation, disorientation, Parkinsonism, psychosis, and manic disorder [14]. As mentioned 
above, IFN therapy can also aggravate the symptoms of peripheral neuropathies.
6. Conclusions
Sometimes EHMs can be the first clinical manifestation of HCV infection. This is why in the 
diagnostic work-up of a patient with the above reported neurological/psychiatric disorders 
without more obvious causes, clinicians should always consider screening for HCV infection.
Antiviral HCV treatment should be the first-line treatment for managing mild-to-moderate vascu-
lar and neurologic symptoms. Persistence or relapse of neurologic symptoms despite viral  clearance 
suggest the presence of other diseases, so further diagnostic work-up should be undertaken.
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